Article
Tasmanian devil CD28 and CTLA4 capture CD80 and CD86 from adjacent cells.
Developmental and comparative immunology - 1 Feb 2021
Wong Candida, Darby Jocelyn M, Murphy Peter R, Pinfold Terry L, Lennard Patrick R, Woods Gregory M, Lyons A Bruce, Flies Andrew S
Abstract excerpt
Immune checkpoint immunotherapy is a pillar of human oncology treatment with potential for non-human species. The first checkpoint immunotherapy approved for human cancers targeted the CTLA4 protein. CTLA4 can inhibit T cell activation by capturing and internalizing CD80 and CD86 from antigen presenting cells, a process called trans-endocytosis. Similarly, CD28 can capture CD80 and CD86 via trogocytosis and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.